EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer

Not Applicable

• Conditions: Esophageal Cancer; Pancreatic Cancer; Stomach Cancer
• Interventions: Procedure: PET/CT and EUS; Behavioral: standard follow-up

• Registration Number: NCT02209415
• Lead Sponsor: Michael Bau Mortensen

Brief Summary

Follow-up after successful operative treatment of cancer in the esophagus, stomach or pancreas in order to detect recurrent disease is a controversial topic.

This is because the methods and the consequence of following these patients is unknown.

Therefore the investigators will randomize these patients in to two groups:

1. One group of patients will be offered visits with a specialist surgeon in a outpatient setting for a clinical evaluation every 3,6,9,12,18 and 24 months after surgery, as is the current standard at our department.

2. The other group will be offered Endoscopic UltraSound, EUS, and PET/CT with the same intervals as the first group.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-04
• Study First Submitted: 2011-11-28
• Status Verified: 2014-08
• Study First Submitted QC: 2014-08-04
• Last Update Submitted: 2014-08-04
• Study First Posted: 2014-08-05
• Last Update Posted: 2014-08-05
• Primary Completion: 2016-01
• Study Completion: 2016-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 182

Inclusion Criteria

• R0- resection for primary adenocarcinoma or squamous cell carcinoma of the esophagus, stomach or pancreas.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention PET/CT and EUS	PET/CT and EUS	PET/CT and EUS at 3,6,9,12,18 and 24 months after surgery
Standard outpatient follow-up	standard follow-up	Outpatient clinic visits 3,6,9,12,18 and 24 mths after surgery

Primary Outcome Measures

Name	Time	Method
Number of patients eligible for treatment	2 years	Does early detection of recurrent disease translate in to more patients being eligible for oncologic treatment?

Trial Locations

Locations (1)

Center for Surgical Ultrasound, Department of upper surgical gastroenterology; 🇩🇰 Odense, Region of Southern Denmark, Denmark